A citation-based method for searching scientific literature

Matthias S Matter, Obinna Chijioke, Spasenija Savic, Lukas Bubendorf. Transl Lung Cancer Res 2020
Times Cited: 3







List of co-cited articles
10 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Optimizing Mutation and Fusion Detection in NSCLC by Sequential DNA and RNA Sequencing.
Danielle Cohen, Liesbeth M Hondelink, Nienke Solleveld-Westerink, Sandra M Uljee, Dina Ruano, Anne-Marie Cleton-Jansen, Jan H von der Thüsen, S Rajen S Ramai, Pieter E Postmus, Jacob F Graadt van Roggen,[...]. J Thorac Oncol 2020
21
33

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.
Oliver Gautschi, Julie Milia, Thomas Filleron, Juergen Wolf, David P Carbone, Dwight Owen, Ross Camidge, Vignhesh Narayanan, Robert C Doebele, Benjamin Besse,[...]. J Clin Oncol 2017
166
33

ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.
Alan E Wakeling, Simon P Guy, Jim R Woodburn, Susan E Ashton, Brenda J Curry, Andrew J Barker, Keith H Gibson. Cancer Res 2002
709
33

Rociletinib in EGFR-mutated non-small-cell lung cancer.
Lecia V Sequist, Jean-Charles Soria, Jonathan W Goldman, Heather A Wakelee, Shirish M Gadgeel, Andrea Varga, Vassiliki Papadimitrakopoulou, Benjamin J Solomon, Geoffrey R Oxnard, Rafal Dziadziuszko,[...]. N Engl J Med 2015
473
33

U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors.
Kyriakos P Papadopoulos, Erkut Borazanci, Alice T Shaw, Ryohei Katayama, Yuki Shimizu, Viola W Zhu, Thomas Yang Sun, Heather A Wakelee, Russell Madison, Alexa B Schrock,[...]. Clin Cancer Res 2020
19
33

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.
Neal I Lindeman, Philip T Cagle, Mary Beth Beasley, Dhananjay Arun Chitale, Sanja Dacic, Giuseppe Giaccone, Robert Brian Jenkins, David J Kwiatkowski, Juan-Sebastian Saldivar, Jeremy Squire,[...]. Arch Pathol Lab Med 2013
315
33

KRAS-Mutant non-small cell lung cancer: From biology to therapy.
Irene Ferrer, Jon Zugazagoitia, Stephan Herbertz, William John, Luis Paz-Ares, Gerald Schmid-Bindert. Lung Cancer 2018
103
33

A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma.
Toyoaki Hida, Vamsidhar Velcheti, Karen L Reckamp, Hiroshi Nokihara, Pallavi Sachdev, Tomoki Kubota, Takuya Nakada, Corina E Dutcus, Min Ren, Tomohide Tamura. Lung Cancer 2019
32
33

Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non-Small-Cell Lung Cancer: Findings From a Real-Life Cohort.
Elizabeth Dudnik, Jair Bar, Nir Peled, Elias Bshara, Teodor Kuznetsov, Aharon Yonathan Cohen, Tzippy Shochat, Hovav Nechushtan, Amir Onn, Abed Agbarya,[...]. Clin Lung Cancer 2019
5
33

Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component.
Paul K Paik, Anna M Varghese, Camelia S Sima, Andre L Moreira, Marc Ladanyi, Mark G Kris, Natasha Rekhtman. Mol Cancer Ther 2012
36
33

Characterization of ROS1 cDNA from a human glioblastoma cell line.
C Birchmeier, K O'Neill, M Riggs, M Wigler. Proc Natl Acad Sci U S A 1990
90
33

Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
Giorgio Scagliotti, Joachim von Pawel, Silvia Novello, Rodryg Ramlau, Adolfo Favaretto, Fabrice Barlesi, Wallace Akerley, Sergey Orlov, Armando Santoro, David Spigel,[...]. J Clin Oncol 2015
187
33

EGF-ERBB signalling: towards the systems level.
Ami Citri, Yosef Yarden. Nat Rev Mol Cell Biol 2006
33

Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC.
Christian Rolfo, Philip C Mack, Giorgio V Scagliotti, Paul Baas, Fabrice Barlesi, Trever G Bivona, Roy S Herbst, Tony S Mok, Nir Peled, Robert Pirker,[...]. J Thorac Oncol 2018
261
33

Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.
Yunpeng Yang, Jianya Zhou, Jianying Zhou, Jifeng Feng, Wu Zhuang, Jianhua Chen, Jun Zhao, Wei Zhong, Yanqiu Zhao, Yiping Zhang,[...]. Lancet Respir Med 2020
38
33

Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer.
Jessica J Lin, Elizabeth Kennedy, Lecia V Sequist, Priscilla K Brastianos, Kelly E Goodwin, Sara Stevens, Alexandra C Wanat, Lisa L Stober, Subba R Digumarthy, Jeffrey A Engelman,[...]. J Thorac Oncol 2016
66
33

First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance.
Yuxiang Ma, Xin Zheng, Hongyun Zhao, Wenfeng Fang, Yang Zhang, Jieying Ge, Lu Wang, Weicong Wang, Ji Jiang, Shaokun Chuai,[...]. J Thorac Oncol 2018
30
33

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.
Jude Canon, Karen Rex, Anne Y Saiki, Christopher Mohr, Keegan Cooke, Dhanashri Bagal, Kevin Gaida, Tyler Holt, Charles G Knutson, Neelima Koppada,[...]. Nature 2019
481
33

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.
Pasi A Jänne, Michel M van den Heuvel, Fabrice Barlesi, Manuel Cobo, Julien Mazieres, Lucio Crinò, Sergey Orlov, Fiona Blackhall, Juergen Wolf, Pilar Garrido,[...]. JAMA 2017
179
33

Characterization of Computed Tomography Imaging of Rearranged During Transfection-rearranged Lung Cancer.
Masafumi Saiki, Satoru Kitazono, Takahiro Yoshizawa, Yosuke Dotsu, Ryo Ariyasu, Junji Koyama, Tomoaki Sonoda, Ken Uchibori, Shingo Nishikawa, Noriko Yanagitani,[...]. Clin Lung Cancer 2018
5
33

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.
Wei-Sheng Huang, Shuangying Liu, Dong Zou, Mathew Thomas, Yihan Wang, Tianjun Zhou, Jan Romero, Anna Kohlmann, Feng Li, Jiwei Qi,[...]. J Med Chem 2016
142
33

Next Generation Sequencing for Gene Fusion Analysis in Lung Cancer: A Literature Review.
Rossella Bruno, Gabriella Fontanini. Diagnostics (Basel) 2020
16
33

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
J Guillermo Paez, Pasi A Jänne, Jeffrey C Lee, Sean Tracy, Heidi Greulich, Stacey Gabriel, Paula Herman, Frederic J Kaye, Neal Lindeman, Titus J Boggon,[...]. Science 2004
33

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.
Vincent A Miller, Vera Hirsh, Jacques Cadranel, Yuh-Min Chen, Keunchil Park, Sang-We Kim, Caicun Zhou, Wu-Chou Su, Mengzhao Wang, Yan Sun,[...]. Lancet Oncol 2012
726
33

Identifying patients with NTRK fusion cancer.
J P Solomon, R Benayed, J F Hechtman, M Ladanyi. Ann Oncol 2019
61
33

Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802).
Kazutomo Kinoshita, Kohsuke Asoh, Noriyuki Furuichi, Toshiya Ito, Hatsuo Kawada, Sousuke Hara, Jun Ohwada, Takuho Miyagi, Takamitsu Kobayashi, Kenji Takanashi,[...]. Bioorg Med Chem 2012
112
33

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.
D Moro-Sibilot, N Cozic, M Pérol, J Mazières, J Otto, P J Souquet, R Bahleda, M Wislez, G Zalcman, S D Guibert,[...]. Ann Oncol 2019
50
33

Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Alice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, D Ross Camidge, Benjamin J Solomon, Ravi Salgia, Gregory J Riely, Marileila Varella-Garcia, Geoffrey I Shapiro, Daniel B Costa,[...]. N Engl J Med 2014
33

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
Jean-Charles Soria, Enriqueta Felip, Manuel Cobo, Shun Lu, Konstantinos Syrigos, Ki Hyeong Lee, Erdem Göker, Vassilis Georgoulias, Wei Li, Dolores Isla,[...]. Lancet Oncol 2015
271
33


Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.
F Mosele, J Remon, J Mateo, C B Westphalen, F Barlesi, M P Lolkema, N Normanno, A Scarpa, M Robson, F Meric-Bernstam,[...]. Ann Oncol 2020
96
33

Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer.
Roberto Ferrara, Nathalie Auger, Edouard Auclin, Benjamin Besse. J Thorac Oncol 2018
73
33

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
Keunchil Park, Eng-Huat Tan, Ken O'Byrne, Li Zhang, Michael Boyer, Tony Mok, Vera Hirsh, James Chih-Hsin Yang, Ki Hyeong Lee, Shun Lu,[...]. Lancet Oncol 2016
580
33

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.
Hisayuki Shigematsu, Li Lin, Takao Takahashi, Masaharu Nomura, Makoto Suzuki, Ignacio I Wistuba, Kwun M Fong, Huei Lee, Shinichi Toyooka, Nobuyoshi Shimizu,[...]. J Natl Cancer Inst 2005
33

CNS Metastases in Patients With MET Exon 14-Altered Lung Cancers and Outcomes With Crizotinib.
Michael Offin, Jia Luo, Robin Guo, John K Lyo, Christina Falcon, Jordan Dienstag, Olivia Wilkins, Jason Chang, Charles M Rudin, Gregory Riely,[...]. JCO Precis Oncol 2020
3
33

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
Tony S Mok, Yi-Long Wu, Myung-Ju Ahn, Marina C Garassino, Hye R Kim, Suresh S Ramalingam, Frances A Shepherd, Yong He, Hiroaki Akamatsu, Willemijn S M E Theelen,[...]. N Engl J Med 2017
33

The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer.
Pieter E Postmus, Elisabeth Brambilla, Kari Chansky, John Crowley, Peter Goldstraw, Edward F Patz, Hiroyasu Yokomise. J Thorac Oncol 2007
256
33

Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples.
Kurtis D Davies, Anh T Le, Jamie Sheren, Hala Nijmeh, Katherine Gowan, Kenneth L Jones, Marileila Varella-Garcia, Dara L Aisner, Robert C Doebele. J Thorac Oncol 2018
71
33

Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study.
Sébastien Couraud, Fabrice Barlesi, Clara Fontaine-Deraluelle, Didier Debieuvre, Jean-Philippe Merlio, Lionel Moreau, Michèle Beau-Faller, Rémi Veillon, Jean Mosser, Faraj Al Freijat,[...]. Eur J Cancer 2019
8
33

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
Yi-Long Wu, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Seiji Niho, Fumito Tsuji, Rolf Linke, Rafael Rosell, Jesus Corral,[...]. Lancet Oncol 2017
437
33

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.
Lecia V Sequist, Belinda A Waltman, Dora Dias-Santagata, Subba Digumarthy, Alexa B Turke, Panos Fidias, Kristin Bergethon, Alice T Shaw, Scott Gettinger, Arjola K Cosper,[...]. Sci Transl Med 2011
33

Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study.
Byoung Chul Cho, Radka Obermannova, Alessandra Bearz, Mark McKeage, Dong-Wang Kim, Ullas Batra, Gloria Borra, Sergey Orlov, Sang-We Kim, Sarayut L Geater,[...]. J Thorac Oncol 2019
27
33

Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer.
Ibiayi Dagogo-Jack, Pablo Martinez, Beow Y Yeap, Chiara Ambrogio, Lorin A Ferris, Christine Lydon, Tom Nguyen, Nicholas A Jessop, A John Iafrate, Bruce E Johnson,[...]. Clin Cancer Res 2019
36
33

HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.
Rathi N Pillai, Madhusmita Behera, Lynne D Berry, Mike R Rossi, Mark G Kris, Bruce E Johnson, Paul A Bunn, Suresh S Ramalingam, Fadlo R Khuri. Cancer 2017
66
33

HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers.
Bob T Li, Dara S Ross, Dara L Aisner, Jamie E Chaft, Meier Hsu, Severine L Kako, Mark G Kris, Marileila Varella-Garcia, Maria E Arcila. J Thorac Oncol 2016
118
33

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
Lecia V Sequist, Renato G Martins, David Spigel, Steven M Grunberg, Alexander Spira, Pasi A Jänne, Victoria A Joshi, David McCollum, Tracey L Evans, Alona Muzikansky,[...]. J Clin Oncol 2008
651
33

The Catalogue of Somatic Mutations in Cancer (COSMIC).
S A Forbes, G Bhamra, S Bamford, E Dawson, C Kok, J Clements, A Menzies, J W Teague, P A Futreal, M R Stratton. Curr Protoc Hum Genet 2008
557
33

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
Alexander Drilon, Federico Cappuzzo, Sai-Hong Ignatius Ou, D Ross Camidge. J Thorac Oncol 2017
161
33

ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.
Justin F Gainor, Anna M Varghese, Sai-Hong Ignatius Ou, Sheheryar Kabraji, Mark M Awad, Ryohei Katayama, Amanda Pawlak, Mari Mino-Kenudson, Beow Y Yeap, Gregory J Riely,[...]. Clin Cancer Res 2013
361
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.